STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock.